A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.

Main Inclusions/Exclusions:

  • No metastatic urolithial carcinoma
  • No additional malignancies requiring active tx (with some exceptions)
  • No contraindications for general or spinal anesthesia
  • No active autoimmune disease, or any condition requiring immunosuppressants/steroids
  • No history of coagulation issues

Contact: cajwciclinicaltrials@providence.org

Learn more here.